Helsinn Birex Pharmaceuticals Limited has Been Assigned Certain International Rights to Klean-Prep(R) by Helix BioPharma Corp.

By Helsinn Healthcare Sa, PRNE
Tuesday, December 21, 2010

LUGANO, Switzerland, December 22, 2010 - Helsinn Birex Pharmaceuticals Ltd, has been assigned world-wide rights,
title and interest in Klean-Prep(R), excluding Canada, and an exclusive
license for the U.S.

Helsinn, a pharmaceutical group based in Lugano, Switzerland today
announced that it has entered into an agreement and has been assigned by
Helix BioPharma Corp., world-wide rights, title and interest, excluding
Canada, and an exclusive license for the US for Klean-Prep(R), a
pre-treatment for colon examination in colorectal cancer screening. Helsinn
currently has a royalty-bearing license from Helix to sell Klean-Prep(R)
world-wide, excluding the U.S. and Canada.

Helix will retain the Canadian rights to Klean-Prep(R). Helsinn and Helix
have entered into a new supply agreement for Helsinn to supply Klean-Prep(R)
to Helix with terms extending over a ten year period, subject to certain
performance conditions.

"We are delighted to have signed this agreement with Helix for
Klean-Prep(R), an important product, first launched in 1987," said Dr.
Riccardo Braglia, Helsinn group's CEO, "and are pleased to strengthen our
efforts to offering our network of partners, covering 85 countries
world-wide, products which meet the medical community needs and which have a
strong positive impact on patients' quality of life."

About Klean-Prep(R)

Klean-Prep(R) is a modern specialist product for the preparation of the
colon prior to colonoscopy and X-ray examinations. Klean-Prep(R) is a
balanced mixture of polyethylene glycol 3350 (PEG 3350) and electrolytes
which, added to water, produces a clear, colourless, iso-osmotic solution. It
acts as a bowel cleansing agent and allows a total cleansing in 4 to 6 hours.

Klean-Prep(R) can be taken at home and thus reduces hospitalization and
nursing time, it has a high cleansing success rate (95%) and is very well
tolerated. Klean-Prep(R) has achieved excellent sales performances and it is
among the leaders in bowel cleansing preparations, thanks to the top-quality
characteristic of the product combined with partnerships with companies well
introduced in hospitals and diagnostic centres. Klean-Prep(R) is the only
product of its class which provides patients with a most useful and
easy-to-use shaker for the preparation and intake of the solution.

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with headquarters in
Lugano, Switzerland and subsidiaries in Ireland and USA. Helsinn's unique
business model is focused on the licensing of pharmaceuticals and medical
devices in therapeutic niche areas. The Group in-licenses early to late stage
new chemical entities, completes their development from the performance of
pre-clinical/clinical studies and Chemistry, Manufacturing and Control (CMC)
development, to the filing for and attainment of their market approval

Helsinn's products are sold directly, through the Group subsidiaries, or
alternatively out-licensed to its network of local marketing and commercial
partners, selected for their deep in-market knowledge and know-how, and
assisted and supported with a full range of product and scientific management
services, including commercial, regulatory, financial, legal and medical
marketing advice.

The active pharmaceutical ingredients and the finished dosage forms are
manufactured at Helsinn's cGMP facilities in Switzerland and Ireland, and
supplied worldwide to its customers.

Helsinn, with a workforce of around 450 employees in Switzerland, Ireland
and USA, reported a 2009 turnover of over CHF 305.0 million (about EUR 232.0
at the current conversion exchange rate), covering 85 countries
worldwide, with over 20% of this turnover invested in R&D.

For more information on the Helsinn Group please visit the website

    For further information contact:

    Helsinn Healthcare SA
    Paola Bonvicini
    Head of Communication & Press Office
    Tel: +41-91-985-21-21
    E-Mail: info-hhc@helsinn.com

For further information contact: Helsinn Healthcare SA, Paola Bonvicini, Head of Communication & Press Office, Tel: +41-91-985-21-21, E-Mail: info-hhc at helsinn.com

will not be displayed